Skip to content

mbeck

NMIN’s Scientific Director tells the story of the LNP delivery system behind Pfizer’s COVID-19 vaccine

In a January 15, 2021 seminar organized by the Life Sciences Institute of the University of British Columbia, NMIN’s Scientific Director Dr. Pieter Cullis shared a first-hand account of the 40-year scientific journey that culminated in the lipid nanoparticle (LNP) delivery system underpinning the Pfizer/BioNTech vaccine against COVID-19. Watch the… Read More »NMIN’s Scientific Director tells the story of the LNP delivery system behind Pfizer’s COVID-19 vaccine

Nano versus Molecular: Optical Imaging Approaches to Detect and Monitor Tumor Hypoxia – a review by NMIN researcher & trainees

In a review article published today in Advanced Healthcare Materials, NMIN trainees Dr. Miffy Hok Yan Cheng and Yulin Mo, together with NMIN researcher Dr. Gang Zheng, survey the latest nano and molecular developments in optical imaging approaches for detecting and monitoring hypoxia in solid tumours. “Hypoxia is a hallmark… Read More »Nano versus Molecular: Optical Imaging Approaches to Detect and Monitor Tumor Hypoxia – a review by NMIN researcher & trainees

NMIN researchers featured in 30th anniversary issues of Bioconjugate Chemistry

Three reviews by NMIN researchers – Drs Pieter Cullis, Shana Kelley, Dominik Witzigmann, and Gang Zheng – have been honoured with inclusion in 30th anniversary issues of the journal Bioconjugate Chemistry. “Throughout 2020, Bioconjugate Chemistry is holding a year-round celebration with a special group of invited review authors,” comments NMIN… Read More »NMIN researchers featured in 30th anniversary issues of Bioconjugate Chemistry

Canadian technology enables Pfizer’s COVID-19 vaccine

https://youtu.be/M-NUP8Xs9-g Above: watch the 26 April 2021 coverage of this story by GlobalNews. See also the CIHR’s timeline and video “The long road to mRNA vaccines,” featuring the contributions highlighted here. Pfizer caught the world’s attention with its promising early results for a COVID-19 vaccine candidate. What has been less… Read More »Canadian technology enables Pfizer’s COVID-19 vaccine

NMIN research on entrapment of siRNA within LNPs published in Nanoscale

A new article by NMIN researchers published in the journal Nanoscale sheds light on a potential mechanism by which lipid nanoparticle (LNP) formulations of nucleic acid encapsulate short interfering RNA (siRNA). “Genetic drugs based on RNA or DNA have a remarkable potential to treat virtually any disease,” comments NMIN Scientific… Read More »NMIN research on entrapment of siRNA within LNPs published in Nanoscale

Dr. Ellen Wasan receives a $745K CIHR grant to support her NMIN project

NMIN researcher Dr. Ellen Wasan and colleagues have been awarded a five-year CIHR Project Grant worth $745,876 to support and expand upon her NMIN-funded project, “Intranasal Vaccines for Pertussis and Influenza Using Novel Formulations of a Triple Adjuvant.”  The research aims to develop better vaccines—expanding the range of those who… Read More »Dr. Ellen Wasan receives a $745K CIHR grant to support her NMIN project

NMIN researchers discuss gene therapies for skin disease

NMIN researcher Dr. Sarah Hedtrich, her team including NanoCore`s Operational Lead Dr. Dominik Witzigmann, discuss the status of gene therapies as tools for treating skin disease in a review article published in Trends in Biotechnology. “In this review, we discuss current approaches, successes, and failures of cutaneous gene therapy and… Read More »NMIN researchers discuss gene therapies for skin disease

NMIN researchers discover dose threshold for nanoparticle tumour delivery

NMIN researchers and colleagues have discovered a nanoparticle threshold dose that improves nanoparticle delivery and therapy for solid tumours. Published in Nature Materials, the study emerged from Dr. Warren Chan‘s Integrated Nanotechnology & Biomedical Sciences Laboratory at the University of Toronto, with NMIN researchers Drs. Chan and Gang Zheng as… Read More »NMIN researchers discover dose threshold for nanoparticle tumour delivery